As upregulated during AD onset in the absence of CBD treatment, both Rgs7 and its binding protein Rgs7bp play a role in opioid, dopamine, and adrenergic GPCRs as the Gαi/o-type (Masuho et al., 2013). Here, RGS7 is linked to Alzheimer disease.